Live Breaking News & Updates on Versant ventures

Stay informed with the latest breaking news from Versant ventures on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Versant ventures and stay connected to the pulse of your community

Next-Gen PARP Inhibitor Shows Benefit in Breast Cancer Patients

Next-Gen PARP Inhibitor Shows Benefit in Breast Cancer Patients
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Oregon , United-states , Hong-kong , United-kingdom , Switzerland , Texas , Swiss , American , Haihe-biopharma , Biocity-biopharma , Calithera-biosciences , Terremoto-biosciences

Contineum prices biotech's latest IPO, raising $110M for neuroinflammatory drugs

BioPharma

William-blair , Nasdaq , Inception-sciences , Johnson , Bristol-myers-squibb , Contineum-therapeutics , Biopharma-dive , Myers-squibb , Structure-therapeutics , Pipeline-therapeutics , Versant-ventures , Biotech

J&J-Partnered Contineum Corrals $110M From IPO for Clinical Trials in Fibrosis & MS

J&J-Partnered Contineum Corrals $110M From IPO for Clinical Trials in Fibrosis & MS
medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.

Johnson , Bristol-myers-squibb , Nasdaq , Contineum-therapeutics , Diego-based-continuem , Horizon-therapeutics , Contineum-phase , Versant-ventures ,

Lose Fat, Not Muscle: Next Test for Lilly's Zepbound Pairs It With BioAge Drug

In preclinical testing, combining BioAge Labs’ experimental drug with Eli Lilly weight drug Zepbound led to greater weight loss compared with Zepbound alone. Now the company plans to run a Phase 2 study to see if it can replicate those results in humans.

Cambridge , Cambridgeshire , United-kingdom , Redwood-city , California , United-states , Columbus , Ohio , Chapel-hill , Thousand-oaks , Delaware , Deerfield

AbbVie wraps up $64M oncology, immunology deal with Tentarix

AbbVie wraps up $64M oncology, immunology deal with Tentarix
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Richard-gonzalez , Robert-michael , Tentarix-biotherapeutics , Gilead-sciences , Amplitude-ventures , Versant-ventures , Samsara-biocapital , Chief-operating-officer-robert ,

Firefly Bio Debuts With $94 Million Series A Financing

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 15, 2024--

Canada , California , United-states , South-san-francisco , Jerel-davis , Carolyn-bertozzi , Todd-foley , Bernhard-geierstanger , Scott-hirsch , Steve-edelson , John-flygare , Genentech

Versant-backed Firefly Bio wants to make the next generation of ADCs

BioPharma

California , United-states , Carolyn-bertozzi , Eli-lilly , Bernhard-geierstanger , Jerel-davis , Daiichi-sankyo , John-flygare , Scott-hirsch , Astrazeneca-enhertu , Bristol-myers-squibb , Genentech

Firefly Bio Debuts With $94 Million Series A Financing

-- Transformational degrader antibody conjugate company backed by leading syndicate including founding investor Versant Ventures, MPM BioImpact, Decheng Capital and Eli Lilly & Company --SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led b...

Canada , Todd-foley , Bernhard-geierstanger , Scott-hirsch , Carolyn-bertozzi , Jerel-davis , John-flygare , Eli-lilly-company , Genentech , Basel-technology-park , Leadership-team , Linkedin

Enterprise Therapeutics closes £26 million ($33.1 million) Series B follow-on financing

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.

Italy , Italian , Rob-woodman , Enterprise-therapeutics-ltd , Novartis-venture-fund , Ip-group , Versant-ventures , Epidarex-capital , Therapeutics , Iopharmaceutical , Hronic , Ystic-fibrosis

Augmedics CEO takes over corner office at CVRx

CVRx (Nasdaq:CVRX) announced today that it appointed Kevin Hykes as its new president and CEO, effective Feb. 12.

Ali-behbahani , Kevin-hykes , Nadim-yared , Relievant-medsystems , Cameron-health , Medtronic , Versant-ventures ,